Cytotoxicity, Immunologic
Research News and Information

Tuesday, November 24, 2009

Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of T-lymphocyte in human bladder tumor cell S in vitro.

30 Oct 2009 OBJECTIVES: The aim of this study was to investigate whether dendritic cells (DCs) transfected with human secondary lymphoid-tissue chemokine (hSLC) and human interleukin-2 (hIL-2) genes are capable of improving DC's proliferation and to produce a ... Read more...

Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.

17 Oct 2009 Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma in humans. The aggressive activated B cell-like (ABC) subtype of DLBCL is characterized by constitutive NF-kappaB activity and requires signals from CARD11, BCL10, and the ... Read more...

Masking MALT1: the paracaspase's potential for cancer therapy.

17 Oct 2009 A key feature of aggressive B cell lymphomas is constitutive NF-kappaB activation, which requires signals from the CARD11-BCL-10-MALT1 (CMB) complex. The unique enzymatic activity of MALT1 degrades one of its binding partners, BCL-10, as well as the ... Read more...

Latest indexed articles for 'Cytotoxicity, Immunologic'

These are the very latest articles for this heading:

• Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of T-lymphocyte in human bladder tumor cell S in vitro. 30 Oct 2009
• Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. 17 Oct 2009
• Masking MALT1: the paracaspase's potential for cancer therapy. 17 Oct 2009
• Kinetics of early T cell receptor signaling regulate the pathway of lytic granule delivery to the secretory domain. 14 Oct 2009
• The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse. 14 Oct 2009
• A view to a kill: how ligand quality controls lethal hits. 14 Oct 2009
• Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. 13 Oct 2009
• NK cells protect secondary lymphoid tissue from cytomegalovirus via a CD30-dependent mechanism. 29 Sep 2009
• Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. 29 Sep 2009
• The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following different administration routes. 29 Sep 2009
• The developmental role of natural killer cells at the fetal-maternal interface. 29 Sep 2009
• Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. 29 Sep 2009
• Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. 13 Sep 2009
• Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice. 12 Sep 2009
• CRTAM confers late-stage activation of CD8+ T cells to regulate retention within lymph node. 12 Sep 2009
• The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. 11 Sep 2009
• Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. 9 Sep 2009
• Killer Ig-like receptor ligand mismatch directs NK cell expansion in vitro. 9 Sep 2009
• Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. 2 Sep 2009
• Sustained and NK/CD4+ T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus. 2 Sep 2009

See a longer list of these articles.

Technical information about 'Cytotoxicity, Immunologic'

Definition: The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.

Descriptor UI: D003602

Alternative terms: Cytotoxicity, Immunologic; Immunologic Cytotoxicity; Immunologic Tumoricidal Activities; Tumoricidal Activities, Immunologic; Tumoricidal Activity, Immunologic; Immunologic Tumoricidal Activity;

Related Mesh Headings: Killer Cells, Natural; T-Lymphocytes, Cytotoxic; Complement Membrane Attack Complex; Killer Cells, Lymphokine-Activated; Antibodies, Bispecific;

Allowable Qualifiers: drug effects; genetics; immunology; physiology; radiation effects; ethics;

Tree Number: G12.425.270;

History Note: 78

Technical Notes: note category: reserve for process: do not confuse with CYTOTOXICITY TESTS, IMMUNOLOGIC; DF: CYTOTOX IMMUNOL